NexpowderTM*
endoscopic hemostasis

Immediate hemostasis. Low rebleeding rates. Minimal scattering or catheter clogging.

Webinar

Innovations in Endoscopic Hemostasis

Dr. Gabriel Rahmi and Prof. Timo Rath discuss the latest innovations in endoscopic hemostasis.

Watch the webinar now

 

 

 

A hemostatic powder that puts you in control

The Nexpowder™* endoscopic hemostatic system is a noncontact, nonthermal and nontraumatic hemostatic powder sprayed through a catheter. Featuring a proprietary powder-coating technology, Nexpowder™* minimizes catheter clogging and particle scattering, 1-3 giving you more control and better visibility.

Why Nexpowder™*?

  • A proprietary powder coating technology that minimizes catheter clogging and particle scattering 
  • Unique delivery system that doesn’t rely on CO2 or air compressors
  • Distinctive blue color so you can have the confidence the lesion is fully covered
  • Highly adhesive gel that reacts to moisture, not just active bleeding, so it can be used in a variety of clinical applications

94%

immediate hemostasis rate4

2x

 the adhesive force of other hemostatic sprays5

3.7%

rebleeding rate3

Hemostatic powder technology that puts you in control.3,4,5

The Nexpowder™* endoscopic hemostasis system is a powder that can be sprayed to an ulcer site, applying an endoscopic hemostatic agent. As a hydrophilic biocompatible adhesive material, it is composed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran. 

The Nexpowder™* system forms the adhesive gel after making contact with the water or blood by reversible crosslinking. Crosslinked gel helps prevent bleeding, loss of body fluid and contamination of the ulcer site by adhering to the bleeding site in the gastrointestinal tract and then gel degrades within 1 day to 3 days.3,4,5

Clinical experience

Nexpowder™* case video by D. Lee

Watch this Nexpowder™* case video by D. Lee, Division of Gatroenterlogy, Department of Internal Medicine.

Nexpowder™* case video by Prof. Rath

Watch this Nexpowder™* case video by Prof. Rath, Head of the Ludwig Demling Endocscopy Center, University Hospital of Erlangen, Germany.

Nexpowder™* endoscopic hemostasis system clinical summary

A prospective study assessed the feasibility of Nexpowder™* application in refractory upper gastrointestinal bleeding in 17 patients, and has shown:

  • Successful application in all patients
  • Initial hemostasis in 16 out of 17 patients: 94%.
  • Rebleeding within 30 days was seen in 3 out of 16 patients (19%)
  • Remnants of the gel was evident in 11 out of 16 patients (69%) at the second examination after 24 hours1

In a retrospective study in Korea, monotherapy with Nexpowder™* was administered to 56 patients with active bleeding. Immediate hemostasis was achieved in 96.4% (54/56) with a rebleeding rate of 3.7% (2/54) and no adverse events.2

Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Authors: Jongbeom Shin et al. 
Published in: BMC Gastroenterol (2021) 21:40

Conclusion: In conclusion, this single-arm study demonstrated Nexpowder™* was associated with excellent immediate hemostasis rate and safety profile as well as low rebleeding for upper gastrointestinal tumor bleeding.

Interested in learning more?

Contact us to learn more about our product solutions and how our portfolio could benefit you and your patients.

Contact us

Nexpowder™* procedure

Nexpowder™* endoscopic hemostatic system

These instructions provide a step-by-step guide on how to setup and use the Nexpowder™* endoscopic hemostatic system. 

Watch the instructional video or download the procedural guide.

Nexpowder™* cases

In this video, you can watch an overview of Nexpowder™* being applied in the following cases:

  • Peptic ulcer bleeding
  • Gastric cancer bleeding
  • Post-gastric ESD bleeding
  • Salvage therapy ESD bleeding

Events & Education

Nexpowder™* 
online training

In this online training, you will learn about:

  • Nexpowder™* product and technology 
  • Nexpowder™* clinical efficiency 
  • Indications for Nexpowder™*
  • Product handling
  • Best practice

Nexpowder™* 
nurse webinar

Real world experience webinar using Nexpowder™* to solve a variety of gastrointestinal bleeds.

Speakers:

  • Dr. Rehan Haidry, Consultant Gastroenterologist, UCLH London
  • MS. Ray-Nina Magcaling, Endoscopy Senior Staff Nurse, UCLH London
     

Innovations in endoscopic hemostatic powder

ESGE webinar

Access the Medtronic ESGE webinar and hear from the experts about a new endoscopic hemostasis system for active bleeds and prevention of delayed bleeding after resection.

Interested in learning more?

Contact us to learn more about our product solutions and how our portfolio could benefit you and your patients.

Contact us
References

™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company

1. Antunes C, Copelin II EL. Upper Gastrointestinal Bleeding. [Updated 2019 Sep 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470300/

2. Raphaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. Clin Colon Rectal Surg. 2012;25(4):219-227. doi:10.1055/s-0032-1329393

3. Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec; 7(12):E1763-E1767.

4. Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May; 51(5):458-462.

5. Bang B, Lee E, Maeng J, et al. Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model. PLoS One. 2019 Jun 11; 14(6):e0216829.